Why Is ADAPTIVE BIOTECHNOLO (ADPT) Stock Up Today?
By the Top Tier Newswire AI Desk · September 24, 2026 at 10:37 AM ET · reviewed against 5 wire stories
ADAPTIVE BIOTECHNOLO (ADPT) is up +5.06% in the latest session. Our newswire has captured 5 stories on ADPT across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ADPT stock is up today
ADPT stock rose 5.06% to $29.30 in early trading on Thursday, driven by renewed investor attention to adaptive technologies and recent developments in the biotech sector. The stock opened at a slight discount but quickly reversed to post a strong intraday gain, reaching a session high of $29.30. The move appears to be fueled by a broader market narrative around adaptive materials and diagnostics, as well as coverage of Adaptive Biotechnologies’ role in updated cancer guidelines.
What Happened
The rise in ADPT came amid a series of recent announcements in the adaptive technology space. Scarlet Therapeutics announced a partnership with DARPA to develop adaptive smart red blood cells, while the Smart Materials Market was highlighted as a sector poised for significant growth through 2034. These developments, though not directly tied to Adaptive Biotechnologies, contributed to a thematic lift for the stock. Additionally, Adaptive Biotechnologies was mentioned in updated NCCN guidelines for multiple myeloma, which included its clonoSEQ test for minimal residual disease assessment. This news reinforced the company’s position in the oncology diagnostics space. Analyst activity also supported the stock, with BTIG raising its price target to $34 and maintaining a Buy rating.
What The Data Shows
The stock’s intraday performance showed a strong reversal after a -0.5% opening gap. It reached a session high of $29.30 at 10:35 AM ET and traded at $29.23 by the close of the session. Volume was 0.3 million shares, or 0.1 times the 3-month average, suggesting a relatively quiet but focused session. Adaptive Biotechnologies is currently unprofitable, with a trailing twelve-month EPS of -0.41 and a net margin of -20.7%. However, revenue is growing at a 50.1% rate. The stock is trading at a market cap of $4.4 billion and has a beta of 2.10, indicating above-market volatility. The 52-week range is $12.00 to $28.78, and the stock closed the session near its 52-week high.
What To Watch
The company is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments related to the NCCN guideline updates and the competitive landscape in oncology diagnostics.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ADPT · today's session (5-min) · +5.36% vs prior close · updated 3:24 PM ETAI sentiment, last 36h · averaged over 5 stories · 65/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoPR NewswireBULLISH 63General
XIP Advises SMT Energy on $268 Million Equity Partnership with Climate Adaptive Infrastructure
Parent-level equity partnership provides long-term capital to accelerate SMT's battery storage development, ownership and operating platform NEW YORK, Sept. 24, 2026 /PRNewswire/ -- SMT Energy ("SMT"), a developer, owner and operator of battery energy storage systems, has entered into an...
1d agoGlobeNewswireBULLISH 63General
$69.2Bn Smart Materials Market Set for Strong Growth Through 2034 as Demand for Adaptive Technologies Expands Across Industries
Demand is rising for energy-efficient smart materials in healthcare, electronics, automation, EVs and construction, creating opportunities in sensors,...
1d agoGlobeNewswireBULLISH 67Product/PR
Scarlet Therapeutics Secures DARPA Agreement to Develop Adaptive Smart Red Blood Cells
BRISTOL, United Kingdom, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics Ltd (‘Scarlet’), a biotech company developing red blood cell-based therapeutics, today announced that it has entered into an agreement with the Defense Advanced...
1d agoBusiness InsiderBULLISH 63Product/PR
Scarlet Therapeutics Secures DARPA Agreement to Develop Adaptive Smart Red Blood Cells
BRISTOL, United Kingdom, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics Ltd (‘Scarlet’), a biotech company developing red blood cell-based therapeutics, today announced that it has entered into an agreement with the Defense Advanced...
1d agoYahoo TopBULLISH 67Product/PR
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The update strengthens the case for monitoring minimal residual disease, or […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →